PLAQUE PSORIASIS

This study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…

This study tests an oral medication called deucravacitinib in teenagers aged 12 to 17 with moderate to severe plaque psoriasis. The goal is to see if the drug safely improves skin clearance and reduces itching compared to a placebo. About 366 participants will take the pill daily…

This study looks at the long-term safety and how well ORKA-001 works for adults with moderate-to-severe plaque psoriasis. Participants must have completed a previous Oruka Therapeutics study. The main goal is to track side effects and see if skin clearing is maintained or improve…

This study tests a new oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. About 140 adults aged 18-70 will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.

This study tests a medicine called zasocitinib in children and teens aged 4 to 17 with moderate-to-severe plaque psoriasis. The goal is to see how well it clears skin and if it is safe. Participants will take the medicine or a placebo for 16 weeks, then all will get the real medi…

This study tests an experimental drug called D-2570 in people with moderate to severe plaque psoriasis. About 477 adults will receive either D-2570, a placebo, or an active comparator drug. The goal is to see if D-2570 safely reduces skin symptoms and improves quality of life.

This study tests the long-term safety of two oral drugs—deucravacitinib and ustekinumab—in about 3,040 adults with moderate-to-severe plaque psoriasis who also have at least one heart risk factor (like smoking, high blood pressure, or diabetes). Participants will be randomly assi…

This study tests an experimental drug called D-2570 in 390 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either D-2570 or a placebo (inactive pill) for 16 weeks. The main goal is to see if the drug can clear at least 90% of skin sy…

This study tests an experimental drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. The main goal is to see if the drug can reduce psoriasis symptoms by at least 75% after 12 weeks. Participants must have had psoriasis for at least 6 mon…

This study tests a new cream (MC2-01) against a standard gel and a placebo in 537 Chinese adults with plaque psoriasis. The goal is to see if the cream clears skin better after 8 weeks of daily use. Participants apply the cream at home and attend check-ups to track skin improveme…

This study tests an oral drug called deucravacitinib in children aged 4 to 18 with moderate to severe plaque psoriasis. The goal is to see if it safely reduces skin symptoms and improves quality of life. About 153 participants will receive either the drug or a placebo, and those …

This study tests whether adding two simple questions about morning stiffness and lower back pain to a standard screening tool can help doctors spot psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults in Canada who are candidates for bi…

This early-stage study tests whether a new tablet called UA026 is safe and how it works in the body. It involves 124 people, including healthy volunteers and those with moderate to severe plaque psoriasis. The goal is to find the right dose and check for side effects, not yet to …

This study tests an experimental pill called CS32582 in adults with moderate to severe plaque psoriasis. The trial has two parts: a small dose-finding phase and a larger 12-week treatment phase involving about 200 people. Researchers will check if the drug safely reduces skin sym…

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will measure how the drug affects quality of life, including skin symptoms and daily activities, over up to 2.5 years. Participants continue…

This study tests a new medicine called ORKA-002 for people with moderate-to-severe plaque psoriasis. About 160 adults will receive either the drug or a placebo to see if it can clear skin and reduce symptoms. The goal is to find the best dose and check for side effects.

This study tests whether taking high-dose vitamin D3 pills along with a standard steroid cream works better than the cream alone for mild-to-moderate psoriasis. About 24 adults will use the cream for 4 weeks, then be split into two groups: one gets vitamin D, the other a placebo …

This study collects skin samples from people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. The goal is to analyze genes and other markers to better understand what causes these inflammatory skin diseases. No treatment is given; it is purely for …